Aims We assessed how opioid agonist treatment (OAT) for opioid use disorder (OUD),
specifically methadone and buprenorphine, including buprenorphine‐naloxone, is delivered …

We summarise the evidence for medicinal uses of opioids, harms related to the extramedical
use of, and dependence on, these drugs, and a wide range of interventions used to address …

Opioid agonist treatment (OAT) is the primary intervention for opioid use disorder (OUD) in
Canada and the USA. Yet, a number of barriers contribute to sub-optimal treatment uptake …

Abstract Objectives In March 2020, the Substance Abuse and Mental Health Services
Administration permitted Opioid Treatment Programs (OTPs) to relax restrictions on take …

As harm reduction programs and services proliferate, people who use drugs (PWUD) are
increasingly subjected to surveillance through the collection of their personal information …

Background: Prior to the COVID-19 pandemic, the United States (US) was already facing an
epidemic of opioid overdose deaths. Overdose deaths continued to surge during the …

Background Emergency contingency guidelines for opioid agonist treatment (OAT) were
introduced in Ireland in March 2020, to ensure rapid and uninterrupted access to treatment …

Fentanyl and its analogues have played an increasing role in opioid overdose deaths
across the country over the past decade. Such high-potency, non-prescription opioids are …

Introduction Opioid use disorder (OUD) is a debilitating illness that remains a serious public
health issue in the United States. Use of telemedicine to deliver m edications for the …

Importance Amid rapid and widespread adoption of telehealth-based opioid treatment
(TBOT), there is an urgent need for rigorous studies exploring the feasibility and …